Interestingly, higher expression of the FOXC1 signature conferred a significantly greater probability of relapse-free survival in only the Luminal B (Fig. 6e) and HER2+ breast cancer patients (Supplementary Figure 5H, I). The gene discussed is ERBB2; the disease is breast cancer.